Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra’s computer assisted vacuum thrombectomy (CAVT) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density (HD) mapping and pulsed field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter.

Oct. 27, 2024 — HeartFlow, Inc.  recently announced seven-year data confirming the use of HeartFlow’s AI-enabled fractional flow reserve computed tomography (FFRCT) and Plaque Analysis in the assessment of long-term risk of coronary artery disease (CAD) in clinically stable, symptomatic patients. The data show the HeartFlow platform provides clinicians with the insights needed to anticipate and mitigate adverse events, including myocardial infarctions, in symptomatic patients with stable chest pain.

Oct. 30, 2024 — HeartLung Technologies, a developer of AI tools for early detection of heart disease, lung cancer and other conditions announced that its AI-enabled Automated Cardiac Chambers Volumetry (AutoChamber) recently received “Breakthrough Medical Device” designation and marketing authorization from the U.S. Food and Drug Administration.

Impella ECP pump insertion. 

 

Oct. 28, 2024  — Results from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference in Washington, D.C.

Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and a global leader in heart recovery.

 

Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX Coronary Bioadaptor System compared to contemporary Resolute Onyx zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient population subsets from the INFINITY-SWEDEHEART RCT.

Oct. 24, 2024 – Royal Philips and Medtronic Neurovascular have announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term disability. As leaders in stroke diagnosis and treatment, the two organizations are advocating on raising awareness around the potential health and economic benefits for patients, their families and societies of improving access to timely stroke diagnosis and treatment.

Oct. 23, 2024 – The Society for Vascular Surgery (SVS) is launching a three-year patient education campaign, Highway to Health, to empower Americans to learn their SVS Strong Vessel Score and start a conversation with their doctor to see if a vascular surgeon could be a good addition to their overall care team.

Earlier this year, Materialise, a global supplier of 3D printing software and services, acquired FEops, a Belgian company that develops AI-driven simulation technology to improve procedure efficiency and clinical outcomes for structural heart interventions.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now